Market news

A notable acquisition unfolded on September 29, as Botzer, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 60,000 shares in an SEC filing. What Happened: A Form 4 filing from the U.S.

A notable acquisition unfolded on September 29, as Davidi, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 86,500 shares in an SEC filing. What Happened: Davidi, Board Member at

Disclosed in a recent SEC filing, Lilach Asher Topilsky, Director at Kamada (NASDAQ:KMDA), made a strategic move by acquiring company stock options on September 29,. What Happened: Disclosed in a Form 4 filing on

Kamada (NASDAQ:KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions. The comp

A noteworthy insider acquisition was disclosed on September 24, as Payorski, Director at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 60,000 shares. What Happened: Payorski, Director at Kamada,

A significant insider transaction involving the exercise of company stock options was reported on September 24, by Boris Gorelik, VP at Kamada (NASDAQ:KMDA), as per the latest SEC filing. What Happened: Disclosed in a

A substantial insider move unfolded on September 25, as London, Chief Executive Officer at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 800,000 shares in an SEC filing. What Happened: In a Form 4

Disclosed in a recent SEC filing, David Tsur, Board Member at Kamada (NASDAQ:KMDA), made a strategic move by acquiring company stock options on September 23,. What Happened: Revealed in a Form 4 filing on Wednesday with

A noteworthy insider acquisition was disclosed on September 23, as Nir, VP at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 112,500 shares. What Happened: Disclosed in a Form 4 filing on Wednesday

A substantial insider move unfolded on September 23, as Itshayek, Director at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 46,000 shares in an SEC filing. What Happened: In a recent Form 4 filing

Hanni Neheman, VP at Kamada (NASDAQ:KMDA), reported acquisition of company stock options on September 23, according to a new SEC filing. What Happened: In a Form 4 filing with the U.S. Securities and Exchange Commission

A noteworthy insider acquisition was disclosed on September 23, as Dekel, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 46,000 shares. What Happened: In a recent Form 4 filing with

Chaime Orlev, Chief Financial Officer at Kamada (NASDAQ:KMDA), reported acquisition of company stock options on September 23, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and

In a new SEC filing on September 23, it was unveiled that Livneh, VP at Kamada (NASDAQ:KMDA), acquired stock options for 89,485 shares. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on

A substantial acquisition of company stock options by Leon Recanati, Board Member at Kamada (NASDAQ:KMDA) was reported on September 23, based on a new SEC filing. What Happened: Disclosed in a Form 4 filing on Wednesday

In a recent SEC filing, it was disclosed that Karnit Goldwasser, Board Member at Kamada (NASDAQ:KMDA), made a noteworthy acquisition of company stock options on September 24,. What Happened: In a Form 4 filing with the

In a new SEC filing on September 23, it was unveiled that Tsur, Director at Kamada (NASDAQ:KMDA), acquired stock options for 37,500 shares. What Happened: Revealed in a Form 4 filing on Wednesday with the U.S.

Detailed price information for Kamada Ltd (KMDA-Q) from The Globe and Mail including charting and trades.

Complete stats, fight record, and career highlights for Yusuke Kamada. Latest news, upcoming fights, and detailed MMA history at MMA Junkie.

Detailed price information for Kamada Ltd (KMDA-Q) from The Globe and Mail including charting and trades.

U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million AnnuallyKamada’s Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA

Detailed price information for Kamada Ltd (KMDA-Q) from The Globe and Mail including charting and trades.

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel. Mr. London is sch

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company’s or

Dividend to be Paid Consistent with the Company's Cash Dividend PolicyREHOVOT, Israel and HOBOKEN, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that its Board of Directors has declared a cash dividend of $0.17 (approximately NIS 0.50) per share on the Company’s ordinar

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tipranks Press Release.

Kamada Ltd (KMDA) reports its strongest quarter ever with $54.9 million in revenue, a 23% year-over-year increase, while reiterating its full-year guidance.

Moby summary of Kamada Ltd.'s Q2 2026 earnings call

Kamada (NASDAQ:KMDA) reported record revenue and adjusted EBITDA for the second quarter and first half of 2026, driven by higher sales of its specialty plasma-derived products, including KEDRAB, VARIZIG and HEPAGAM. The company reiterated its full-year guidance and said it expects initial sales unde

Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Motley Fool Press Release.

Kamada (KMDA) delivered earnings and revenue surprises of +33.33% and +6.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that Chaime Orlev, its Chief Financial Officer (CFO), will transition out of his role to pursue other opportunities, effective December 31, 2026. Kamada has a search underway to identify a succe

Kamada (KMDA) Chief Financial Officer Chaime Orlev will leave the company to pursue other opportunit

In a new SEC filing on August 6, it was revealed that Recanati, Director at Kamada (NASDAQ:KMDA), executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S. Securities and

In a new SEC filing on August 6, it was revealed that Payorski, Board Member at Kamada (NASDAQ:KMDA), executed a significant exercise of company stock options. What Happened: Payorski, Board Member at Kamada, exercised

Highlighted on August 6, it was unveiled in an SEC filing that Davidi, Director at Kamada (NASDAQ:KMDA), executed a significant transaction involving the exercise of company stock options. What Happened: Davidi,